5.2% of combined E.coli, K.pneumoniae, and P.mirabilis isolates were ESBL (extended spectrum beta-lactamase) positive
Streptococcus anginosus group includes: S. anginosus, S. constellatus, S. intermedius
Viridans group Streptococci include: S.mitis/oralis, S.parasanguinis, S.salivarius, S.sanguinis, S.mutans
5.2% of combined E.coli, K.pneumoniae, and P.mirabilis isolates were ESBL (extended spectrum beta-lactamase) positive
5.2% of combined E.coli, K.pneumoniae, and P.mirabilis isolates were ESBL (extended spectrum beta-lactamase) positive
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
